Sarepta Therapeutics Inc. 已正式向美国食品药品监督管理局(FDA)提出会面请求,旨在讨论提交补充新药申请(sNDA)的相关事宜。此次会议将聚焦于新药申请材料的准备与提交策略。
Sarepta Therapeutics Inc. 已正式向美国食品药品监督管理局(FDA)提出会面请求,旨在讨论提交补充新药申请(sNDA)的相关事宜。此次会议将聚焦于新药申请材料的准备与提交策略。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.